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Abstract
Background: Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment,
decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF).
These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury,
shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding
sigh to PSV (the PROTECTION study).
Methods: PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units
(ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and undergoing PSV from 4 to 24 h will be
enrolled. All patients will first undergo a 30-min sigh test by adding sigh to clinical PSV for 30 min to identify early
oxygenation responders. Then, patients will be randomized to PSV or PSV + sigh until extubation, ICU discharge, death
or day 28. Sigh will be delivered as a 3-s pressure control breath delivered once per minute at 30 cmH2O. Standardized
protocols will guide ventilation settings, switch back to controlled ventilation, use of rescue treatments, performance of
spontaneous breathing trial, extubation and reintubation. The primary endpoint of the study will be to verify the
feasibility of PSV + sigh evaluated through reduction of failure to remain on assisted ventilation during the first 28 days
in the PSV + sigh group versus standard PSV (15 vs. 22%). Failure will be defined by switch back to controlled
ventilation for more than 24 h or use of rescue treatments or reintubation within 48 h from elective extubation. Setting
the power to 80% and first-risk order to 5%, the computed size of the trial is 129 patients per arm.
Discussion: PROTECTION is a pilot randomized controlled trial testing the feasibility of adding sigh to PSV. If positive, it
will provide physicians with an effective addition to standard PSV for lung protection, able to reduce failure of assisted
ventilation. PROTECTION will provide the basis for a future larger trial aimed at verifying the impact of PSV + sigh on
28-day survival and ventilator-free days.
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Background
Although mechanical ventilation is an effective support
strategy for patients with acute hypoxic respiratory fail-
ure (AHRF), it has the potential to aggravate lung dam-
age through the development of ventilation-induced
lung injury (VILI) [1]. Ever since a landmark study dem-
onstrated the association between the use of high tidal
volumes during controlled mechanical ventilation and
increased mortality [2], “protective” controlled ventila-
tion with limited volume and pressure has become the
recommended treatment for patients with AHRF, in
order to minimize the risk of VILI [3]. Volutrauma and
barotrauma (i.e., the key mechanisms causing VILI dur-
ing controlled ventilation) might also occur during
assisted ventilation, if excessive force generated by the
respiratory muscles adds to the pressure delivered by the
ventilator to determine high tidal volume and injurious
transpulmonary pressure [4]. However, while protective
strategies have been established for patients undergoing
controlled mechanical ventilation (e.g., limiting plateau
pressure to < 30 cmH2O), interventions that enhance
lung protection during assisted ventilation are still lack-
ing [5]. Around 30% of invasively ventilated patients
with AHRF already breath spontaneously by day 1 after
intubation [6] and early implementation of specific strat-
egies to enhance lung protection during assisted ventila-
tion may have a tremendous impact on clinical practice.
From a pathophysiological standpoint, during assisted
ventilation, derecruitment and lung heterogenity may facili-
tate the generation of high regional barotrauma and volu-
trauma [7], thus increasing the risk of VILI [8–10]. The
addition of cyclic short sustained inflations (sigh) to assisted
ventilation is known to optimize recruitment and decrease
heterogeneity in patients with AHRF [11–16]. Moreover,
sigh might reduce the inspiratory effort and the tidal
volume [11–16]. These physiologic studies generated the
hypothesis that addition of sigh to pressure support ventila-
tion (PSV, the most common assisted mechanical ventila-
tion mode) might decrease the risk of VILI, potentially
yielding faster weaning and improved clinical outcomes.
As prospective clinical trials including long-term use
of sigh during assisted ventilation have not been per-
formed yet, we conceived a pilot randomized controlled
trial (RCT) to verify the clinical feasibility of the addition
of sigh to PSV (PSV + sigh) in comparison to standard
PSV. Therefore, the objective of the present trial is to
determine whether ventilation by PSV + sigh can be
applied early and safely in intubated patients with AHRF
and successfully maintained until extubation. Specific-
ally, the primary endpoint is to evaluate whether PSV +
sigh, as compared to PSV, is associated with reduced
failure of assisted ventilation, with failure defined as (1)
prolonged switch to controlled ventilation; (2) use of res-
cue therapies for refractory hypoxia or (3) early need for
reintubation after elective extubation.
Methods
Design
The PROTECTION (Pressure support ventilation + sigh
in acute hypoxemic respiratory failure patients) trial is
an investigator-initiated, international, multicenter,
parallel randomized controlled two-arm trial that will be
performed in intubated and ventilated patients with
AHRF, who are admitted to the intensive care unit
(ICU). The study will be conducted in adherence to the
principles of the World Medical Association’s Declar-
ation of Helsinki and in accordance with the Medical
Research Involving Human Subjects Act (WMO). Ethics
approval will be sought from each participating institu-
tion before starting enrollment and consent will be
obtained for each patient following local regulations.
The Institutional Review Board of the coordinating
center approved the protcol on 12 June 2017 under
reference number 318_2017bis. The trial was registered
at www.clinicaltrials.gov with code NCT03201263 in
June 2017. The Standard protocol items: recommenda-
tion for interventional trials (SPIRIT) checklist can be
found in Additional file 1 and the SPIRIT figure is
included in the main body of the manuscript (Fig. 1).
Setting
The PROTECTION trial will be performed in the ICUs
of 23 centers around the world (12 in Italy, 10 in other
European countries, 1 in China). The coordinating cen-
ter will be Policlinico Maggiore Hospital in Milan, Italy.
Study population
Consecutive patients admitted with AHRF to each par-
ticipating ICU, who have been intubated and switched to
PSV between 1 and 7 days after intubation will be
screened between 4 and 24 h from the start of PSV. Fur-
ther inclusion criteria will be partial arterial pressure of
oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio ≤
300 mmHg (measured at clinical positive end-expiratory
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pressure (PEEP) and FiO2 values); clinical PEEP ≥ 5
cmH2O and stable Richmond Agitation-Sedation Scale
(RASS) value of − 2 to 0. Exclusion criteria will be clinical
PEEP ≥ 15 cmH2O; partial pressure of arterial carbon di-
oxide (PaCO2) > 60 mmHg; arterial pH < 7.30; PaO2/FiO2
ratio ≤ 100 mmHg (measured at clinical PEEP and FiO2
values); age < 18 years; presence of central nervous system
or neuromuscular disorders; history of severe chronic ob-
structive pulmonary disease or fibrosis; AHRF fully
explained by cardiac failure or fluid overload; evidence of
active air leak from the lung (e.g., pneumothorax); cardio-
vascular instability (e.g., systolic blood pressure (SBP) <
90 mmHg despite vasopressors); clinical suspicion of
elevated intracranial pressure; extracorporeal support;
moribund status and refusal by the attending physician.
If an eligible patient is excluded from participation,
the reason(s) for exclusion will be registered.
The Consolidated Standards of Reporting Trials
(CONSORT) diagram of PROTECTION trial is pre-
sented in Fig. 2.
Sigh test
To explore the possibility of implementing predictive en-
richment in a larger future RCT [17], we planned a
pre-randomization test to assess the prevalence of pa-
tients with AHRF with improved oxygenation after the
introduction of sigh. After enrollment, FiO2 will be ti-
trated to obtain pulse arterial oxygen saturation (SpO2)
of 90–96% maintaining clinical PSV settings including
PEEP; then, all patients will undergo a clinical test of
PSV + sigh to assess the prevalence of improved oxygen-
ation in sigh responders vs. non-responders. To this end,
we will first record the SpO2/FiO2 ratio at the start of
the test; then, 30 min after the introduction of sigh as
the cyclic pressure control phase set at 30 cmH2O for
3 s once per minute [14], SpO2/FiO2 will be collected
again to quantify the number of patients in whom this
ratio increased (i.e., “sigh responders”) [18]. To deliver
sigh, ventilators will be switched to biphasic positive
airway pressure mode with the lower pressure-level set
at clinical PEEP and the higher pressure-level of the sigh
set at 30 cmH2O with a 3-s inspiratory time and then a
57-s expiratory time [16].
Randomization
At the end of the sigh test, patients will be randomized
through an online automatic centralized and computer-
ized system to one of the two study groups (1:1 ratio):
PSV or PSV + sigh. Due to the nature of the interven-
tion, blinding will not be feasible.
Interventions: ventilation strategies for each study arm
PSV group
After randomization, clinicians will set PSV to meet the fol-
lowing targets: tidal volume (Vt) of 6–8 mL/kg of predicted
body weight (PBW), with respiratory rate (RR) 20–35 bpm.
FiO2 will be left as selected before the pre-randomization
sigh test, while PEEP will be left as clinically set.
Fig. 1 Standard protocol items: recommendation for interventional trials (SPIRIT) figure. Schedule of enrolment, interventions, and assessments for
the PROTECTION trial. PSV, pressure support ventilation
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PSV + sigh group
PSV will be set with the same protective targets of the
PSV group (see above) but cyclic pressure control phase
at 30 cmH2O for 3 s delivered once per minute (i.e.,
sigh) [14] will be added. FiO2 will be left as selected be-
fore the pre-randomization sigh test with clinical PEEP.
Adjusting ventilation settings
In both groups, PSV will be adjusted, at least every 8 h, as
follows:
– PSV support will be decreased by 2 cmH2O if Vt >
8 mL/kg PBW and/or RR < 20
– PSV support will be increased by 2 cmH2O if Vt <
6 mL/kg PBW and/or RR > 35 and/or in the
presence of respiratory distress (e.g., marked use of
the accessory muscles)
– PEEP and then FiO2 will be increased by 2 cmH2O
and 0.1 if SpO2 is < 90%
– FiO2 and then PEEP will be decreased by 0.1 and 2
cmH2O if SpO2 is > 96%.
The PSV group will be treated by protective PSV
settings until day 28 or death or performance of a
spontaneous breathing trial (SBT); the PSV + sigh
group will be treated by protective PSV settings with
the addition of sigh until day 28 or death or perform-
ance of a spontaneous breathing trial (SBT). Sigh
settings will be left unchanged until day 28, death or
the SBT.
Fig. 2 The Consolidated Standards of Reporting Trials (CONSORT) diagram of the PROTECTION trial. PaO2, partial pressure of arterial oxygen; FiO2,
fraction of inspired oxygen; PEEP, positive end-expiratory pressure; RASS, Richmond Agitation-Sedation Scale; PaCO2, partial pressure of arterial
carbon dioxide; COPD, chronic obstructive pulmonary disease; PSV, pressure support ventilation
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Switch to controlled mechanical ventilation
In both groups, switch to protective controlled ventilation
will be indicated if patient develops at least one of the fol-
lowing conditions: PSV support > 20 cmH2O; PEEP ≥ 15
cmH2O; unstable hemodynamic status (SBP < 90 mmHg
with vasoactive drug); active cardiac ischemia (dynamic ST
changes on cardiac monitor or electrocardiogram); un-
stable arrhythmias; uncontrolled hypertension (SBP >
180 mmHg); abrupt decrease in the level of consciousness
(RASS <− 3); dangerous agitation (RASS > + 2); pH < 7.30;
PaO2/FiO2 ratio ≤ 100 mmHg; necessity to perform diag-
nostic test (e.g., computed tomography (CT scan) or
bronchoscopy).
Controlled ventilation will be set on volume mode
with Vt 6–8 mL/kg PBW, RR to control pH, unchanged
PEEP and FiO2. Controlled ventilation will be thereafter
adjusted according to clinical evolution. Patients
switched to controlled ventilation will be reassessed at
least every 8 h and they will be switched back to PSV or
PSV + sigh (to maintain study group assignment) target-
ing the aforementioned settings and adjustments as soon
as all the following conditions are met: patient is able to
trigger ventilator breaths; PaO2/FiO2 > 100 mmHg; PEEP
< 15 cmH2O; pH ≥ 7.3; stable hemodynamic status with
stable or decreasing doses of vasopressors for ≥ 6 h.
Rescue therapies
In the case of desaturation (SpO2 ≤ 90%) it will be crucial
to exclude hemodynamic impairment as a possible cause.
Also, airway obstruction and ventilator malfunction must
be ruled out. Provided those factors are excluded, a rescue
step-up strategy will be allowed: institution of protective
controlled mechanical ventilation (see above for settings)
and performance of recruitment maneuvers at 40–50
cmH2O, PEEP ≥ 15 cmH2O, prone positioning and in-
haled nitric oxide, extracorporeal membrane oxygenation.
Patients undergoing controlled ventilation and rescue
treatments will be reassessed at least every 8 h and
switched back to PSV or PSV + sigh (to maintain study
group assignment) with the aforementioned settings and
adjustments as soon as all the following conditions are
met: patient can trigger ventilator breaths; PaO2/FiO2 >
100 mmHg; PEEP < 15 cmH2O; pH ≥ 7.3 and stable
hemodynamic status with stable or decreasing doses of
vasopressors for ≥ 6 h.
Weaning protocol and criteria for reintubation
SBT
Patients with SpO2 ≥ 90% on FiO2 ≤ 0.4 and PEEP ≤ 5
cmH2O, no agitation, hemodynamically stable with nor-
epinephrine ≤ 0.1 μg/kg/min or equivalent and at a
stable or decreasing dose for 6 h [19] and without any of
the aforementioned criteria for switch to controlled ven-
tilation will undergo the SBT. For patients in the PSV
group, the attending physician will perform the SBT dir-
ectly. For patients in the PSV + sigh group, the attending
physician will first withdraw sigh, wait 60 min and confirm
the criteria: if confirmed, the SBT will be performed; if
not, sigh will be reintroduced and the clinical criteria will
be checked again to repeat the procedure after at least 8 h.
The SBT will last at least 60 min with a combination of
PEEP 0–5 cm H2O and PSV 0–5 cm H2O. At the end of
the 60 min, the patient will fail the SBT if any of the fol-
lowing are present: criteria to start the SBT not confirmed;
sustained (> 5 min) respiratory rate > 35 bpm; heart rate >
140 bpm; SBP > 180 or < 80 mmHg; marked complaint of
dyspnea; increased somnolence with elevated PaCO2 and/
or pH < 7.3; active cardiac ischemia (dynamic ST changes
on cardiac monitor or electrocardiogram); abrupt decrease
in the level of consciousness with RASS <− 3 or if cough
is not strong enough to clear secretions.
Patients who fail the SBT will be switched back to
PSV or PSV + sigh (to maintain study group assignment)
and clinical criteria will be checked again to repeat the
procedure after at least 6 h.
Patients who pass the SBT will be extubated or, in the
presence of tracheostomy, mechanical ventilation will be
discontinued. If a patient is reintubated or mechanically
ventilated through a tracheostomy again within 48 h, PSV
or PSV + sigh (to maintain study group assignment) will be
restored. If a patient remains extubated or separated from
the ventilator for > 48 h data collection only will continue.
Reasons for reintubation
After elective extubation, reintubation should be promptly
performed if at least one of the following criteria is
present: cardiac arrest; respiratory arrest (respiratory
pauses with loss of consciousness or gasping for air);
respiratory failure with SpO2 < 90% and/or RR > 35 bpm
despite non-invasive ventilation; decreased level of con-
sciousness impairing ability to protect airway; hemoptysis
or hematemesis impairing ability to protect airway; abun-
dant secretions that cannot be effectively cleared or are
associated with lobar collapse, acidosis, hypoxemia or
change in mental status; surgical/invasive procedure
requiring sedation/anesthesia +/− neuromuscular block-
ade such that patient is no longer be able to sustain
unassisted breathing or hemodynamic instability with SBP
< 80 mmHg despite vasoactive drugs.
Standard of care
In all patients, standard of care for intubated patients with
hypoxemic acute respiratory failure (e.g., restrictive fluid
strategy, early appropriate antibiotics, prophylaxis of gastric
stress ulcer and deep vein thrombosis, semi-recumbent
positioning, respiratory physiotherapy, adequate nutrition,
monitoring of sedation, pain and delirium, tracheostomy
and non-invasive ventilation for post-extubation respiratory
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failure) will be granted throughout the whole ICU stay in
accordance to local protocols.
End of follow up
Enrolled patients will be observed until day 28, ICU dis-
charge or death, whichever comes first.
Study endpoints
Primary endpoint
The primary endpoint will be to verify the clinical feasi-
bility of PSV + sigh vs. PSV. Feasibility will be assessed
by comparing the number of patients in each group ex-
periencing at least one of the following failure criteria
[20]: switch to controlled ventilation following presence
of one of the aforementioned reasons for ≥ 24 h con-
secutively; use of PEEP ≥ 15 cmH2O, prone positioning,
inhaled nitric oxide, extracorporeal membrane oxygen-
ation or reintubation within 48 h from extubation fol-
lowing one of the aforementioned reasons.
Secondary endpoints
The study will also provide a preliminary evaluation of the
safety of PSV + sigh by comparing the incidence of the fol-
lowing adverse events in the two study groups:
hemodynamic instability with hypotension (i.e., SBP <
90 mmHg) despite vasoactive drugs; arrhythmias with heart
rate < 40 or > 140 bpm; radiographic evidence of baro-
trauma (i.e., pneumothorax, pneumomediastinum, pneu-
matocoele or subcutaneous emphysema or new chest tube
placement.
Furthermore, it will quantify the prevalence of
short-term (i.e., within 30 min) and long-term (i.e., within
24 h in the PSV + sigh group) sigh responders defined by
improved oxygenation. Finally, it will assess the following
clinical outcomes: 28-day mortality; ventilator-free days;
PSV level, PEEP value and oxygenation index on day 1–3;
number of days on assisted ventilation until day 28; use of
rescue treatments; number of quadrants involved on chest
x-ray on day 1–5; ICU and hospital length of stay and
tracheostomies. The listed variables will be analyzed by
comparing the two study groups considering, first, the
whole study population and, then, only patients who im-
proved oxygenation during the pre-randomization sigh
test (sigh responders).
Data collection
At enrollment, before the sigh test we will anonymously
collect patients’ demographic information (e.g., age, sex,
height, weight), past (e.g., hypertension, chronic medica-
tions) and recent (e.g., etiology of the acute respiratory
failure, days since intubation) medical history, severity of
lung injury (e.g., ventilation setting, arterial blood gases,
respiratory system compliance, diagnosis of acute respira-
tory distress syndrome (ARDS)) and of systemic
involvement (e.g., presence of shock, number of organ fail-
ures) and finally, ventilation data (e.g., RR, Vt, PEEP, FiO2,
PSV level).
In both groups, for the first 24 h, we will assess the
SpO2/FiO2 ratio, RR and PSV tidal volume every 4 h to
further characterize physiologic response to sigh over time.
From day 1 (i.e., within 24 h from randomization) to
day 28 or death or discharge from the ICU, the following
data will be collected every day between 6:00 and 10:00
in the morning: arterial SpO2, arterial and central venous
blood gas analyses, ventilation settings and pattern (i.e.,
sigh pressure level, sigh tidal volume, PSV level, PSV
tidal volume, respiratory rate, PEEP, FiO2, minute venti-
lation, P0.1, mean airway pressure), heart rate, arterial
blood pressure, central venous pressure, cumulative fluid
balance, patient’s comfort assessed using a visual analog
scale (VAS), RASS value, SOFA score and dosage of
sedative agents and vaso-active drugs.
Moreover, each day we will collect information on use
of rescue treatments (i.e., recruitment manoeuvers, use
of PEEP ≥ 15 cmH2O, prone positioning, inhaled nitric
oxide, extracorporeal membrane oxygenation), tracheos-
tomy, switch from the allocated treatment to the other
study arm for ≥ 24 h, switch to controlled ventilation for
≥ 24 h, reason for switch to controlled ventilation, ad-
verse events (i.e., hemodynamic instability with
hypotension with SBP < 90 mmHg despite vasoactive
drugs; arrhythmias; radiographic evidence of barotrauma
with pneumothorax, pneumomediastinum, pneumato-
coele, or subcutaneous emphysema), SBT performance
and reason for SBT failure, extubation or separation
from mechanical ventilation, reintubation and reason for
reintubation with time. We will collect data on day 28
for all enrolled patients on mortality, extubation that oc-
curred outside the ICU and readmission to ICU.
Statistical considerations
Statistical support for the PROTECTION trial will be
granted by collaboration with Dr Carla Fornari and Dr Sara
Conti from the Research Center on Public Health,
Department of Medicine and Surgery, University of
Milano-Bicocca, Monza, Italy. Drs Fornari and Conti are
PhD statisticians with experience in public health and
physiologic studies and they participated to PROTEC-
TION study conception, draft of the study protocol, per-
formed the power analysis to decide sample size and
prepared the data analysis plan.
Sample size
The sample size was computed based on the hypothesis
that PSV + sigh might decrease the rate of failure of
assisted ventilation compared to standard PSV. Based on
previous data [21], the expected proportion of failure in
patients undergoing PSV will be 22% and we
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hypothesized a proportion of 15% for patients in the
PSV + sigh group. Assuming non-inferiority of PSV + sigh
treatment, with a tolerance of 5% we estimated that a
sample size of 258 patients (with 129 patients per study
arm) will be sufficient to assess feasibility of the PSV +
sigh strategy in this pilot phase with power of 0.8 and
alpha 0.05.
Statistical analysis
Continuous normally distributed variables will be
expressed by their mean and standard deviation or as me-
dians and their interquartile ranges when not normally
distributed. Categorical variables will be expressed as
number and proportion (%). To assess the feasibility of
PSV + sigh as compared to PSV (i.e., the primary end-
point), we will compute the proportion of patients experi-
encing at least one of the following events in each arm:
switch to controlled ventilation for ≥ 24 h consecutively;
use of PEEP ≥ 15 cmH2O, prone positioning, inhaled ni-
tric oxide, extracorporeal membrane oxygenation or rein-
tubation within 48 h from extubation.
We will compare the two proportions using the
one-tailed non-inferiority test for proportions with a 5%
tolerance. We will use 0.05 as the significance level. The
same method will be adopted to evaluate the safety of
PSV + sigh, which is a secondary endpoint. Prevalence of
sigh responders in the two arms will be compared using
the chi-squared or Fisher’s exact test. Ventilator-free
days will be calculated as the difference between the
duration of follow up (up to 28 days) and the number of
days of intubation before successful extubation or separ-
ation from mechanical ventilation for tracheostomized
patients. For all the secondary endpoints, we will use the
chi-squared or Fisher’s exact test in the case of binary
variables or the t test or Wilcoxon signed rank test for
continuous variables. Time to death or extubation will
be analyzed using Kaplan-Meier survival curves. Adjus-
tement for potential confounding factors will be evalu-
ated using appropriated regression models.
Study organization
The steering committee is composed of two principal
investigators (TM and LB) plus seven international
experts on ventilation who contributed to the design
and revision of the study protocol. Each participating
center will indicate a local investigator in charge of
the study. The principal investigators are responsible
for administrative management and communication
with the local investigators and for helping the
participating clinical sites in trial management, record
keeping and data management. The local investigators
provide structural and scientific leadership. They
guarantee the integrity of data collection and ensure
timely completion of the case report forms.
Collected data will be entered in an electronic case re-
port form (eCRF) available online at a dedicated website
(https://sighprotection.digitalcrf.eu), with protected indi-
vidual access for each participating center. Patient data
will be anonymous and coded according to a number.
The eCRF includes tools to promote data quality, such
as range checks for data values. Data monitoring will be
performed by means of queries on the database done by
statisticians and analyzed to identify abnormalities and
inconsistencies.
Based on clinical experience and results of physio-
logic studies, the additional risks for patients enrolled
in the PSV + sigh arm is expected to be minimal in
comparison to standard of care. Still, specific patient
insurance will be granted to cover all unexpected ad-
verse events caused by the study interventions and all
adverse events will be monitored by and reported to
the coordinating center.
Discussion
PROTECTION is a pilot randomized controlled trial to
test the long-term clinical feasibility of the addition of sigh
to PSV in comparison to standard PSV. If positive, it will
provide the basis for a future larger trial aimed at verifying
the impact of PSV + sigh on a composite outcome end-
point including 28-day survival and ventilator-free days.
Moreover, it will provide physicians a physiologically
sound addition (i.e., sigh) to standard PSV for lung protec-
tion able to favor assisted ventilation.
Mortality remains considerably high (around 40%) in
intubated patients with AHRF [6]. The clinical severity
of lung injury at presentation and early appropriate
treatment are the main determinants of patients’ out-
comes [19]. However, while the lungs recover, VILI
might significantly impact survival [1]. Recent studies
testing strategies that enhance lung protection (e.g., early
referral to an extracorporeal membrane oxygenation
(ECMO) center [22]; use of muscle relaxants during the
first 48 h after intubation [23]; early use of extended ses-
sions of prone positioning [24]) yielded significantly de-
creased mortality. However, such trials enrolled only the
most severely ill patients with AHRF on controlled
mechanical ventilation. A recent large observational
study [6], instead, showed that most ventilated patients
admitted to the ICU have mild to moderate AHRF or
ARDS that leads to considerably high mortality (≈ 35%)
anyway. Moreover, the same study reported that around
30% of invasively ventilated patients with AHRF and
ARDS are on some form of spontaneous breathing from
day 1 after intubation, independent of the severity of
their illness [6], and this proportion likely increases
within 1 week. Thus, there is an urgent need for inter-
ventions that increase lung protection during assisted
ventilation.
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Key determinants of VILI in patients with AHRF under-
going assisted ventilation include elevated ventilation
pressures and inspired fraction of O2 (FiO2) [25]; hetero-
geneous distribution of alveolar collapse that increases the
regional tidal volume/end expiratory lung volume (Vt/
EELV) ratio (i.e., the regional lung strain) [8] and strenu-
ous inspiratory effort and low regional compliance that
determines elevated regional transpulmonary pressure
(i.e., the regional lung stress) [10]. To this end, previous
studies showed that the addition of sigh to assisted mech-
anical ventilation improves oxygenation without increas-
ing ventilation pressures and FiO2; decreases the tidal
volumes by decreasing the patient’s inspiratory drive; in-
creases the EELV by regional alveolar recruitment; de-
creases regional heterogeneity of lung parenchyma;
decreases patients’ inspiratory efforts limiting transpul-
monary pressure and improves regional compliance [11–
16, 26]. Of note, the improvement in gas exchange and
lung mechanics disappears after sigh discontinuation [12].
In conceiving this study, we reasoned that long-term
application of sigh during PSV might decrease the risk of
VILI through various synergic mechanisms, possibly
decreasing the duration of mechanical ventilation and
mortality in patients with AHRF. To date, no RCT has
tested the long-term safety and feasibility of the applica-
tion of sigh. Therefore, before testing the effects of sigh on
clinical outcome in a RCT, the feasibility of long-term use
of sigh had to be investigated: this is the primary aim of
the PROTECTION trial. Moreover, data on the safety of
sigh will be collected, evaluating potential adverse effects
including development of pneumothorax or other signs of
barotrauma and hemodynamic instability. Finally, the
sample size was calculated based on a potential deacrese
in failure to remain on assisted ventilation from 22%
during PSV to 15% during PSV + sigh, so that the poten-
tial to promote spontaneous breathing by addition of sigh
will already be tested.
We anticipate the PROTECTION trial to be highly feas-
ible, as study procedures are mainly limited to ventilation
settings and do not include complex interventions, with
limited burden on daily activities. PSV + sigh is an
easy-to-implement ventilation mode and, for the present
study, we will use high-performance ICU ventilators already
available in each clinical unit, dramatically decreasing the
study costs.
Even though PROTECTION might be a largely prag-
matic study, the protocol specifically suggests adjust-
ments of ventilation settings and weaning procedures.
Moreover, criteria for switch to controlled ventilation,
use of rescue therapies and reintubation are pre-defined
by the study protocol. Since return to controlled mech-
anical ventilation can occur due to reasons not related
to failure of assisted ventilation (e.g., necessity to per-
form diagnostic or therapeutic procedures requiring
deep sedation and neuromuscular blockade), the proto-
col stresses the importance of periodic reassessment (at
least every 8 h) to restore assisted ventilation as soon as
clinical conditions permit. To this end, failure of assisted
ventilation is defined when controlled ventilation is
maintained for at least 24 h. In summary, the PROTEC-
TION study protocol limits discretional settings and
clinical decisions that might interfere with the primary
outcome.
One important limitation of the PROTECTION trial is
that blinding is not possible due to the nature of the
intervention, and this could induce bias. However, all
the processes that can influence the primary outcome
are regulated by the protocol and all the analyses will be
performed in a blinded fashion. Second, even though a
lower sigh rate might be regarded as more physiological
[15], in the absence of conclusive data on sigh “mini-
mum effective dose” [14], we chose a rate of one per mi-
nute because this can be performed by all the clinically
available high-performance ICU ventilators, increasing
feasibility and decreasing costs, especially of the future
larger RCT. Finally, we did not plan any biomolecular
analysis to verify the impact of addition of sigh on lung
protection for budget reasons; in any case, we will col-
lect a huge amount of physiological data during the
whole study period that will allow reconstruction on
mechanistic effects underlying the clinical benefits.
In conclusion, PROTECTION is a pilot randomized
controlled trial to test the feasibility of long-term addition
of sigh to PSV. Its results could provide a ready-to-use
treatment enhancing successful application of assisted
ventilation. Moreover, PROTECTION will be the basis for
planning a future larger trial investigating the use of sigh
as a strategy to improve hard clinical outcomes in patients
with AHRF undergoing assisted ventilation through
enhanced lung protection.
Trial status
The PROTECTION trial is currently recruiting patients.
The protocol was approved by the coordinating center
Institutional Review Board on 12 June 2017. The first
patient was enrolled on 20 December 2017. Sixteen cen-
ters already received approval from the local ethical
committees and are actively recruiting patients. Recruit-
ment is expected to be completed in November 2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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